Viagra Ingredient Launched For Pulmonary Arterial Hypertension, UK
Featured ArticleMain Category: Cardiovascular / Cardiology
Article Date: 08 Mar 2006 - 16:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3.64 (11 votes) |
| Healthcare Prof: | |
4 (3 votes) |
Revatio has been launched in the UK for the treatment of pulmonary arterial hypertension (PAH), a rare lung disorder that most commonly affects women aged 20-40. Revatio has the same active ingredient as Viagra - sildenafil.
Revatio was launched in Germany in January, 2006 and in the USA in August, 2005.
Revatio was approved in the European Union in November, 2005.
Approximately 100,000 people globally suffer from PAH.
Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/articles/39115.php>
APA
http://www.medicalnewstoday.com/articles/39115.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
